|Bid||0.0000 x 4000|
|Ask||0.0000 x 4000|
|Day's Range||2.8800 - 2.9900|
|52 Week Range||1.5400 - 3.8800|
|Beta (3Y Monthly)||1.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 28, 2017 - Jul 31, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Lexington, Massachusetts-based company said it had net income of 12 cents per share. The biotechnology company posted revenue of $8.6 million in the period. The company's shares closed at $2.66. A ...
- Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - ...
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Agenus, Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...
LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...
For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long ter...
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells. The first patient in the trial was dosed by Dr. Steven J. O'Day, M.D., Executive Director of the John Wayne Cancer Institute & Cancer Clinic, and a pioneer in delivering immune therapies to patients with cancer. Dr. O'Day's pivotal work has led to the approvals of commercial antibodies targeting CTLA-4 and PD-1. "AGEN1181 represents an important next-generation breakthrough with its potential for enhanced immune activation and tumor fighting abilities," said Dr. O'Day.
LEXINGTON, Mass., March 21, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020. Dr. Manuel Hidalgo, MD, PhD, joins as Strategic Advisor. Dr. Hidalgo, an internationally renowned oncologist, has led clinical development of more than 50 novel anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer.
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 40 cents. The biotechnology company posted revenue of $5.4 million in the period. For the year, the company reported ...
- Gilead collaboration results in cash infusion of $150M ; first milestone payment of $7.5M triggered - CTLA-4 & PD-1 trials are accruing for planned BLA filing as early as 2020 - Next-Gen CTLA-4 advancing ...
LEXINGTON, Mass., March 13, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today that the FDA has accepted the company's IND filing for AGEN1423 - a milestone in its partnership with Gilead Sciences, Inc. This milestone triggered a cash payment of $7.5M. Agenus is eligible to receive additional milestone payments in 2019 and beyond.
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
LEXINGTON, Mass., Feb. 19, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today the launch of its Biotech Electronic Security Token (BEST), the first digital-security offering in healthcare. Agenus will host a conference call and live audio webcast today at 11:00 a.m. ET to discuss the launch of BEST and provide a full briefing on the digital security and offering process. Agenus previously announced that BEST is designed to be an innovative and transformative way to finance drug development by increasing liquidity, minimizing dilution, and improving capital allocation. BEST is envisioned as a way to democratize financing through targeted investments for specific therapeutic drug products.